80 Les biomarqueurs moléculaires en oncologie
46. Im A P, Sehgal A R , Carroll M P, et al. (2014) DNMT3A and IDH mutations in acute
myeloid leukemia and other myeloid malignancies: associations with prognosis and
potential treatment strategies. Leukemia [advance online publication]
47. Cazzola M, Della Porta M and Malcovati L (2013) The genetic basis of myelodysplasia and
its clinical relevance Blood 122: 4021-4034
48. Garcia-Manero G (2012) Myelodysplastic syndromes: 2012 update on diagnosis, riskstratification, and management. Am J Hematol 87: 692-7011
49. Greenberg PL1, Tuechler H, Schanz J, Sanz G, et al. (2012) Revised international
prognostic scoring system for myelodysplastic syndromes Blood. 120: 2454-65
50. Bejar R, Stevenson K, Abdel-Wahab O, et al. (2011) Clinical effect of point mutations in
myelodysplastic syndromes.N Engl J Med. 364: 2496-506
51. Sebaa A, Ades L, Baran-Marzack F, et al. (2012) Incidence of 17p deletions and TP53
mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Genes Chromosomes Cancer. 51: 1086-92
52. Kohlmann A, Grossmann V, Nadarajah N, et al. (2013) Next-generation sequencing -
feasibility and practicality in haematology. Br J Haematol 160: 736-53
53. Stiehl T, Baran N, Ho AD, Marciniak-Czochra A (2014) Clonal selection and therapy
resistance in acute leukaemias: mathematical modelling explains different proliferation
patterns at diagnosis and relapse. J R Soc Interface 11: 20140079
46. Im A P, Sehgal A R , Carroll M P, et al. (2014) DNMT3A and IDH mutations in acute
myeloid leukemia and other myeloid malignancies: associations with prognosis and
potential treatment strategies. Leukemia [advance online publication]
47. Cazzola M, Della Porta M and Malcovati L (2013) The genetic basis of myelodysplasia and
its clinical relevance Blood 122: 4021-4034
48. Garcia-Manero G (2012) Myelodysplastic syndromes: 2012 update on diagnosis, riskstratification, and management. Am J Hematol 87: 692-7011
49. Greenberg PL1, Tuechler H, Schanz J, Sanz G, et al. (2012) Revised international
prognostic scoring system for myelodysplastic syndromes Blood. 120: 2454-65
50. Bejar R, Stevenson K, Abdel-Wahab O, et al. (2011) Clinical effect of point mutations in
myelodysplastic syndromes.N Engl J Med. 364: 2496-506
51. Sebaa A, Ades L, Baran-Marzack F, et al. (2012) Incidence of 17p deletions and TP53
mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Genes Chromosomes Cancer. 51: 1086-92
52. Kohlmann A, Grossmann V, Nadarajah N, et al. (2013) Next-generation sequencing -
feasibility and practicality in haematology. Br J Haematol 160: 736-53
53. Stiehl T, Baran N, Ho AD, Marciniak-Czochra A (2014) Clonal selection and therapy
resistance in acute leukaemias: mathematical modelling explains different proliferation
patterns at diagnosis and relapse. J R Soc Interface 11: 20140079